<DOC>
	<DOCNO>NCT00003773</DOCNO>
	<brief_summary>RATIONALE : IM-862 may stop growth ovarian cancer stop blood flow tumor . PURPOSE : Phase I trial study effectiveness IM-862 treating patient recurrent ovarian cancer treatment chemotherapy surgery .</brief_summary>
	<brief_title>IM-862 Treating Patients With Recurrent Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose IM-862 administer intranasally patient recurrent ovarian cancer . II . Determine toxicity regimen patient population . III . Obtain preliminary data regard efficacy drug patient . IV . Evaluate effect drug serum level vascular endothelial growth factor transform growth factor population . OUTLINE : This dose escalation study . Patients receive IM-862 intranasally daily . Treatment continue 6 month absence unacceptable toxicity disease progression . At physician 's discretion , treatment may give patient still respond 6 month treatment . The dose IM-862 escalate cohort 10-20 patient maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 10 5 20 patient experience dose limit toxicity . PROJECTED ACCRUAL : A total 20-70 evaluable patient accrue study within 6-9 month .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Thymogen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven recurrent ovarian cancer Failed relapse cytoreductive surgery follow platinumbased chemotherapy regimen Measurable evaluable disease Recurrent disease manifest isolated increased level CA125 evaluable disease eligible CA125 least 100 PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) ALT and/or AST great 2.5 time ULN Renal : Creatinine great 2 time ULN Neurological : No evidence moderate peripheral neuropathy great grade 1 Other : Not pregnant Fertile patient must use effective contraception No medical , social , psychological factor interfere compliance PRIOR CONCURRENT THERAPY : Biologic therapy : No prior IM862 No concurrent biologic therapy ( e.g. , interleukin2 interferon ) Chemotherapy : See Disease Characteristics Recovered prior chemotherapy No concurrent antineoplastic cytotoxic agent Endocrine therapy : Not specify Radiotherapy : Recovered prior radiotherapy Surgery : See Disease Characteristics Recovered prior surgery Other : No concurrent investigational drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>